Company / Return on Equity (ROE)
RHYTHM PHARMACEUTICALS, INC. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-141.3%
FY2025
5-year range
-1199.3% / -24.5%
FY2021-FY2025
Trend
+88.2%
vs FY2024
Sector context
#170 of 190
Health Care
What the data says
RHYTHM PHARMACEUTICALS, INC. reports negative total equity of -141.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-141.3% in FY2025 with a 5-year CAGR of -60.9%.
Declined from -108.8% to -141.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -72.8pp
- 5-Year Change
- -60.9pp
- 10-Year Change
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 190This company -141.3% Sector average -50.3%
▼
-180.9% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 88.2% year-over-year.
- Currently 91.0pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -141.3% | +88.2% |
| FY2024 | -1199.3% | -1002.4% |
| FY2023 | -108.8% | -58.7% |
| FY2022 | -68.5% | -179.8% |
| FY2021 | -24.5% | +69.6% |
| FY2020 | -80.5% | -60.7% |
| FY2019 | -50.1% | -66.5% |
| FY2018 | -30.1% | -29.2% |
| FY2017 | -23.3% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026